Heterogeneity in association of remote herpesvirus infections and pediatric MS

Bardia Nourbakhsh1, Alice Rutatangwa2, Michael Waltz3, Mary Rensel4, Manikum Moodley4, Jennifer Graves5, Theron Charles Casper3, Amy Waldman6, Anita Belman7, Benjamin Greenberg8, Manu Goyal9, Yolanda Harris10, Ilana Kahn11, Timothy Lotze12, Soe Mar9, Teri Schreiner13, Gregory Aaen14, Janace Hart9, Jayne Ness10, Jennifer Rubin15, Jan-Mendelt Tillema16, Lauren Krupp17, Mark Gorman18, Leslie Benson18, Moses Rodriguez16, Tanuja Chitnis19, John Rose20, Meghan Candee21, Bianca Weinstock-Guttman22, Xiaorong Shao23, Lisa Barcellos23, Judith James24, Emmanuelle Waubant5 & On behalf of the US Network of Pediatric MS Centers

1Department of Neurology, Johns Hopkins University, Baltimore, Maryland
2Department of Neurology, Stony Brook University Hospital, Stony Brook, New York
3Department of Pediatrics, University of Utah, Salt Lake City, Utah
4Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio
5UCSF Regional Pediatric MS Center, San Francisco, California
6Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
7Louie Center for Pediatric MS at Stony Brook University Hospital, Stony Brook, New York
8University of Texas Southwestern Medical Center, Dallas, Texas
9Washington University Pediatric MS and other Demyelinating Disease Center, Washington University in St. Louis, St. Louis, Missouri
10Center for Pediatric-Onset Demyelinating Disease at the Children’s of Alabama, University of Alabama, Birmingham, Alabama
11Children’s National Medical Center, Washington, District of Columbia
12The Blue Bird Circle Clinic for Multiple Sclerosis, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas
13Rockey Mountain MS Center, Children’s Hospital Colorado, University of Colorado at Denver, Aurora, Colorado
14Pediatric Multiple Sclerosis Center at Loma Linda University Children’s Hospital, Loma Linda University, Loma Linda, California
15Lurie Children’s Hospital of Chicago, Chicago, Illinois
16Mayo Clinic Pediatric MS Center, Mayo Clinic, Rochester, Minnesota
17Pediatric MS Center, New York University, New York, New York
18Pediatric Multiple Sclerosis and Related Disorders Program at Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
19Partners Pediatric MS Center, Massachusetts General Hospital, Boston, Massachusetts
20Department of Neurology, University of Utah, Salt Lake City, Utah
21Primary Children’s Hospital, University of Utah, Salt Lake City, Utah
22The Pediatric MS Center at the Jacobs Neurological Institute, State University of New York at Buffalo, Buffalo, New York
23School of Public Health, University of California, Berkeley, Berkeley, California
24University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Correspondence
Bardia Nourbakhsh, 600 N Wolfe St, Path 627, Baltimore, MD 21287. Tel: +1 410 614 0685; Fax: 410-502-6736; E-mail: bnourba1@jhmi.edu

Funding information
National Institutes of Health (grant number: R01NS071463-04) and NMSS (HC 0165).

Received: 6 July 2018; Revised: 8 August 2018; Accepted: 10 August 2018

Annals of Clinical and Translational Neurology 2018; 5(10): 1222–1228
doi: 10.1002/acn3.636

Abstract

Objective: While prior Epstein–Barr virus (EBV) infection has been consistently associated with subsequent risk of developing multiple sclerosis (MS), the association with other common herpesviruses has been more controversial. Our objectives were to determine whether remote infection with EBV and other common herpesviruses affect the susceptibility to pediatric MS and if there are interactions between genetic and demographic factors and viral infections.

Methods: Cases with pediatric-onset MS or clinically isolated syndrome within 4 years of disease onset, and controls were recruited from 16 American pediatric MS centers. Logistic regression models adjusted for potential confounders assessed the association between case status and serological evidence for past infection with EBV, cytomegalovirus (CMV), Herpes Simplex viruses-1 (HSV-1) and -2. We determined the heterogeneity of the effect of viral infection on the risk of having MS according to race, ethnicity and HLA-DRB1:1501 status.

Results: A total of 356 pediatric cases and 493 controls were recruited. In multivariable models, EBV-viral capsid antigen (VCA) seropositivity was associated...
Introduction

Genetic and environmental risk factors and their interactions determine an individual’s risk of developing multiple sclerosis (MS).1 Approximately 200 common genetic variants that alter the risk of MS onset have been described in white adults2 and HLA-DRB1*15:01 has the largest effect. Environmental risk factors consistently associated with MS susceptibility include prior infection with EBV, exposure to cigarette smoking, vitamin D deficiency and obesity.3 Exposures to commonly encountered viruses EBV, exposure to cigarette smoking, vitamin D deficiency associated with MS susceptibility include prior infection with EBV, exposure to cigarette smoking, vitamin D deficiency and obesity.3 Exposures to commonly encountered viruses EBV, exposure to cigarette smoking, vitamin D deficiency associated with MS susceptibility include prior infection with EBV, exposure to cigarette smoking, vitamin D deficiency and obesity.3

While prior infection with EBV is reported in most patients with adult or pediatric-onset MS,1 a few studies have suggested that remote CMV exposure might decrease the risk of having MS.3,4 Although interactions between genetic and environmental factors have been suspected to modulate MS risk, only a few have been reported5–8 in part due to limited study sample sizes and extent of available data. Patients with pediatric-onset MS may have a higher burden of genetic susceptibility variants and/or a greater dose of environmental exposures, resulting in much earlier disease onset and as such, finding gene-environment interactions may be easier in this age group.

We have reported the association between prior exposure to several herpesviruses and MS susceptibility in pediatric MS4 and suggested evidence for an interaction between HLA-DRB1*15:01 status and HSV-1. Although several other studies investigated the association of prior viral infections and pediatric MS risk,9–13 very few studies examining the risk of MS in relation to previous viral exposures and the possible interactions with age, race and ethnicity have been conducted.14 Using a large case–control study, we aimed to assess the heterogeneity of association between remote infections with common herpesviruses and the risk of pediatric MS in children with a diverse racial and ethnic background.

with increased odds of having MS by 7.4 times (95% CI: 4.5–12.0, P < 0.001). Seropositivity for HSV-1 was also associated with increased odds of having MS (OR 1.54, 95% CI: 1.06–2.25, P = 0.025) but this increase was seen only in Whites (OR = 2.18, 95% CI 1.35–3.52, P < 0.001) and those negative for HLA-DRB1*15:01 (OR = 1.89, 95% CI 1.17–3.03, P = 0.009). The effect of remote EBV infection on the risk of pediatric MS depended on race and HLA-DRB1*15:01 status. Interpretation: EBV seropositivity is strongly associated with pediatric MS, as is HSV-1 seropositivity in subjects negative for HLA-DRB1*15:01. Our report of interactions between select viral exposures, and age, race and DRBI status suggests a complex effect of environmental and genetic risk factors on MS development.

Methods

Participating sites

This is a case–control study of risk factors in pediatric MS (R01NS071463, PI Waubant). The participating centers include University of California San Francisco, State University of New York at Buffalo, Massachusetts General Hospital for Children, Mayo Clinic Rochester, Stony Brook University Medical Center, Texas Children’s Hospital, Baylor, Loma Linda University, Children’s Hospital of Philadelphia, Ann & Robert H. Lurie Children’s Hospital of Chicago, Children’s National Medical Center, Children’s Hospital of Colorado, University of Texas Southwestern/Children’s Medical Center Dallas, Boston Children’s Hospital, University of Alabama, Cleveland Clinic and Washington University School of Medicine in St. Louis. Parents completed a comprehensive environmental questionnaire and data including medical history, demographics and environmental exposures (such as parental smoking) were entered into a central database. Institutional review boards at all participating centers reviewed and approved the study. Assent and consent forms were signed by the participants and one of the parents/guardians before enrollment in the study. Participants were recruited between November 2011 and September 2015.

Study participants

Patients with relapsing MS or clinically isolated syndrome (CIS) with high risk for MS whose initial attack occurred before 18 years of age, whose disease duration was less than 4 years and who had at least two silent MRI lesions were recruited to the study. Case status was confirmed by a review panel of at least two pediatric MS experts. Control subjects included pediatric patients seen at general and specialty pediatric clinics at the same institutions during the same period. They were less than 22 years of age, did not have autoimmune disorders except asthma or eczema or severe health conditions and were never
treated with immunosuppressive medications. Their parents did not have MS. Of note, none of the cases or controls in this study had participated in the research previously published by this group.4

Race and ethnicity were self-reported, based on NIH categories. We categorized the racial subgroups as whites, African-Americans and others. Ethnicity was characterized as Hispanic or non-Hispanic. Socio-economic status (SES) was defined as the highest level of education attained by the participant’s mother. Participants answered an environmental questionnaire and provided blood for serum and DNA.

Viral studies
Batched EBV-viral capsid antigen (VCA), CMV, HSV-1, and HSV-2 assays (serum IgG) were tested at the Oklahoma Medical Research Foundation by commercially available, standardized enzyme-linked immunosorbent assay (ELISA) (Wampole Laboratories, Princeton, NJ) as described previously.15,16 Quality control requirements included calibration and having positive and negative controls that met predefined measures. We did not analyze Epstein-Barr nuclear antigen 1 (EBNA-1) seropositivity as the manufacturing source of EBNA-1 antigen changed during the study resulting in inconsistent results.

HLA-DRB1*15:01 and 15:03 genotyping
DNA samples of cases and control subjects were tested by single-nucleotide polymorphisms (SNPs) for the presence of HLA-DRB1*15:01/15:03 and copy number. We used a validated TaqMan polymerase chain reaction (PCR), as previously described.4

Genetic ancestry inference
In a subset of cases and controls, genetic ancestry was determined. Whole-genome single-nucleotide polymorphism (SNP) analysis was performed on Illumina OmniExpress BeadChip or Illumina Infinium Human OmniExpress Exome.17 Standard quality control (QC) was performed. We used SNPWEIGHTS for ancestry inference (https://www.hsph.harvard.edu/alkes-price/software/). The details are described previously.18 Briefly, whole-genome data of the study participants were strand aligned and merged and following QCs were performed before inferencing genetic ancestry: SNPs with more than 10% missing or with MAF <0.01 were excluded and individuals with less than 90% genotyping rate were removed. These analyses were performed in PLINK v.1.9. Then, SNPWEIGHTS was run on the merged/quality-controlled data using the weights for four major ancestral populations (European, West African, East Asian and Native American). More than 200,000 SNPs were used for inference. The output included three predicted principal components and the inferred percentage ancestry.

Statistical analysis
All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Descriptive statistics for participants’ demographic and clinical data were presented as percentage (%), using mean ± standard deviation (SD) or median (range). Significant differences between cases and controls were tested using Chi-square tests of no association for categorical variables and Kruskal–Wallis tests for continuous variables.

In separate models, we explored the multiplicative interaction between age, race, ethnicity and DRB1 status (HLA-DRB1*15:01/15:03 positive or negative) and the viral serostatus, as well as the interaction between different viral infections (such as interaction between seropositivity of EBV and CMV, EBV and HSV, and HSV and CMV). If the P-value of the interaction term was less than <0.15; we stratified the analysis based on that variable. Age analyses used mean age to stratify the cohort.

Results
Characteristics of cases and controls
We recruited 356 pediatric MS or CIS cases with short mean disease duration (<1 year) and 493 control subjects who provided blood samples at the time of enrollment. Demographics, frequency of seropositivity for EBV-VCA, CMV, HSV-1, and -2 and HLA-DRB1 status of cases and controls are presented in Table 1. Cases were older and the proportion of females among cases was higher than controls.

Viral seropositivity and the risk of pediatric MS
A higher proportion of cases than controls had evidence of prior infection with HSV-1, HSV-2 and EBV (Table 1).
In multivariable logistic regression models adjusted for sex, age, race, ethnicity and SES, seropositivity for EBV-VCA was associated with increased odds of having MS by more than sevenfold (OR: 7.36, 95% CI: 4.50–12.04, P-value <0.001). Serological evidence of prior infection with HSV-1 was also associated with modestly increased odds of developing MS (OR: 1.54, 95% CI: 1.06–2.25, P-value = 0.025), while for the association with HSV-2 was only borderline significant (OR: 1.54, 95% CI: 1.00–2.38, P-value = 0.053). There was no association between CMV serostatus and having pediatric MS (OR: 1.29, 95% CI: 0.92–1.80, P-value = 0.14) (Table 2). Additional adjustment for HLA–DRB1 status in the models did not substantially change the results (data not shown). No significant interaction was found between seropositivity of EBV and CMV, EBV and HSV, or HSV and CMV (data not shown).

**Race and ethnicity**

There was a statistically significant multiplicative interaction between race and HSV-1, HSV-2 and EBV-VCA serostatus on the risk of MS (P-value for the interaction term: 0.006, 0.013 and 0.005, respectively) (Table 3).

| Table 1. Baseline characteristics of the cases and control subjects. |
|---------------|------|------|--------|
| Control       | Case |       | P-value |
| N = 493       | N = 356 |       |         |
| Average       | 14.3 (3.8) | 15.2 (3.2) | <0.001^1 |
| enrollment age (SD) |          |          |         |
| Average disease duration in days (SD) |          |          |         |
| Sex           |          |          |         |
| Male          | 237 (48.1%) | 127 (35.7%) |          |
| Female        | 256 (51.9%) | 229 (64.3%) |          |
| Race          |          |          | <0.001^2 |
| White         | 321 (69.5%) | 224 (67.7%) |          |
| Black         | 80 (17.3%) | 62 (18.7%) |          |
| Other         | 61 (13.2%) | 45 (13.6%) |          |
| Ethnicity     |          |          | <0.001^3 |
| Hispanic or latino | 84 (18.0%) | 108 (31.8%) |          |
| Not hispanic or latino | 383 (82.0%) | 232 (68.2%) |          |
| Mother's education |          |          | <0.001^4 |
| None          | 26 (6.0%) | 35 (11.3%) |          |
| High school or Associate's | 203 (47.0%) | 176 (56.6%) |          |
| Bachelor's or Graduate | 203 (47.0%) | 100 (32.2%) |          |
| Positive for HSV-1 | 97 (20.0%) | 93 (26.4%) | 0.029^5 |
| Positive for HSV-2 | 61 (12.6%) | 65 (18.7%) | 0.015^5 |
| Positive for CMV | 156 (32.0%) | 134 (38.0%) | 0.071^5 |
| Positive for EBV-VCA | 284 (58.2%) | 325 (91.6%) | <0.001^5 |
| Positive for DRB1*15:01 or 15:03 | 109 (22.1%) | 141 (40.2%) | <0.001^5 |

^1Kruskal–Wallis test. ^2Chi-squared test of no association.

| Table 2. Multivariable association between serostatus and the odds of pediatric MS. |
|-----------------|--------|--------|--------|
| Effect for positive vs. negative | Odds ratio | 95% CI | P-value |
| HSV-1            | 1.54   | 1.06–2.25 | 0.025 |
| HSV-2            | 1.54   | 1.00–2.38 | 0.053 |
| CMV              | 1.29   | 0.92–1.80 | 0.142 |
| EBV-VCA          | 7.36   | 4.50–12.04 | <0.001 |

^*Adjusted for age, sex, race, ethnicity, and mother’s highest level of education as a measure of socio-economic status. Further adjusting for DRB1 status did not change the results significantly.

| Table 3. Multiplicative interaction test between serostatus and race, ethnicity, age, and DRB1 status. |
|----------------------------------------------------------|--------|--------|--------|
| Interaction term | P-value |
| HSV-1*race       | 0.006  |
| HSV-2*race       | 0.013  |
| CMV*race         | 0.677  |
| VCA*race         | 0.005  |
| HSV-1*ethnicity  | 0.241  |
| HSV-2*ethnicity  | 0.160  |
| CMV*ethnicity    | 0.238  |
| VCA*ethnicity    | 0.363  |
| HSV-1*age        | 0.711  |
| HSV-2*age        | 0.367  |
| CMV*age          | 0.516  |
| VCA*age          | <0.001 |
| HSV-1*DRB1       | 0.076  |
| HSV-2*DRB1       | 0.176  |
| CMV*DRB1         | 0.478  |
| VCA*DRB1         | 0.151  |

HSV-1 and -2 seropositivity were associated with increased risk of MS only in whites (Table 4). The effect of EBV-VCA seropositivity was stronger in whites, as opposed to African-Americans or others (OR = 10.64, 95% CI: 5.77–19.62, P-value <0.001 in whites; OR = 6.75, 95% CI: 1.42–31.91, P-value = 0.016 in African-Americans; OR = 1.96, 95% CI: 0.52–7.37, P-value = 0.32 in others) (Table 4).

The P-value for the interaction between Hispanic ethnicity and viral serostatus was >0.15 and so this was not explored further (Table 3).

**Age**

There was a significant interaction between EBV-VCA serostatus and age in changing the odds of having MS (P-value of the interaction terms <0.001) (Table 3). We then analyzed the effect of viral status for this marker in children younger than 15 years of age (the mean age of participants in the study) versus those who were 15 years of age and older. Seropositivity for EBV-VCA was more
Table 4. Stratified analysis based on variables in which the P-value of the interaction with the serostatus was <0.15.

| Effect                                      | Odds ratio | 95% CI   | P-value |
|---------------------------------------------|------------|----------|---------|
| Race = White                                |            |          |         |
| HSV-1: positive vs. negative                | 2.18       | 1.35–3.52| 0.001   |
| HSV-2: positive vs. negative                | 2.30       | 1.32–3.99| 0.003   |
| VCA: positive vs. negative                  | 10.64      | 5.77–19.62| <0.001 |
| Race = Black                                |            |          |         |
| HSV-1: positive vs. negative                | 1.43       | 0.63–3.26| 0.395   |
| HSV-2: positive vs. negative                | 1.43       | 0.57–3.59| 0.453   |
| VCA: positive vs. negative                  | 6.75       | 1.43–31.91| 0.016   |
| Race = Other                                |            |          |         |
| HSV-1: positive vs. negative                | 0.36       | 0.11–1.20| 0.096   |
| HSV-2: positive vs. negative                | 0.23       | 0.04–1.26| 0.089   |
| VCA: positive vs. negative                  | 1.96       | 0.52–7.37| 0.319   |
| Stratified analysis based on age            |            |          |         |
| Age < 15                                    |            |          |         |
| VCA: positive vs. negative                  | 3.29       | 1.86–5.84| <0.001  |
| Age ≥ 15                                    |            |          |         |
| VCA: positive vs. negative                  | 1.94       | 1.17–3.03| 0.009   |
| Stratified analysis based on DRB1 status    |            |          |         |
| DRB1*15:01 or 15:03 = positive              |            |          |         |
| HSV-1: positive vs. negative                | 0.93       | 0.47–1.84| 0.828   |
| HSV-1: positive vs. negative                | 1.89       | 1.17–3.03| 0.009   |

**173 of 174 cases in the older age group were positive for EBV-VCA antibody, compared to 127 of 200 for controls. Since there was only one negative case, the model was not stable in this age group.

strongly associated with MS in those who were 15 years of age or older (Table 4).

**DRB1 interaction**

Using multiplicative interaction terms (between carrying HLA-DRB1 allele and viral serostatus) and considering the P-value of <0.15 for further exploration in stratified analysis, the presence of HLA-DRB1 modified the effect of seropositivity for HSV-1 on the risk of pediatric MS (Table 3). HSV-1 positive serostatus was associated with increased odds of having MS only in HLA-DRB1 negative subjects. (Table 4).

Subanalysis of participants with available genetic ancestry data

Genetic ancestry inferences were available for 263 cases and 296 controls. (Tables S1 and S2).

In multivariable logistic regression models adjusted for sex, age, genetic ancestry, ethnicity and socio-economic status, seropositivity for EBV-VCA increased the odds of having MS by more than eight times (OR: 8.26, 95% CI: 4.69–14.53, P <0.001). Although there was no statistically significant association between HSV-1, HSV-2 and CMV serostatus and the risk of pediatric MS in this subset of participants (OR: 1.30, 95% CI: 0.85–2.01, P = 0.23; OR: 1.37, 95% CI: 0.83–2.24, P = 0.22; OR: 1.32, 95% CI: 0.86–1.97, P = 0.17, respectively), the effect sizes were similar to the main analyses and the lack of statistical significance is likely due to the smaller sample size.

**Discussion**

Environmental exposures explain a large proportion of MS risk. In this large, multicenter, multi-racial and multi-ethnic case-control study, we demonstrated that race, genetic background and age change the effects of prior infections with common herpesviruses on the risk of pediatric MS.

Prior EBV infection is thus far the strongest and most consistent environmental factor associated with pediatric and adult-onset MS. Although this association with pediatric MS is seen regardless of race and ethnicity, although the association is stronger in whites, as recently reported in adult-onset MS. Differences in the magnitude of the association of EBV infection with the risk of MS among different races and ethnicities point to potential environment-environment or gene-environment interactions.

We report several additional meaningful interactions that modify the association between EBV and pediatric MS. First, in line with previous reports, we observed that prior EBV infection is a stronger risk factor in carriers of HLA-DRB1*15:01. Although, this synergistic effect suggests possible causality of EBV infection in MS development, there is also a possibility that carrying HLA-DRB1*15:01 affects both the risk of MS and susceptibility to EBV infection. Second, EBV seropositivity is a much stronger risk factor in older versus younger children which raises the possibility of a different pathophysiology in this age group.

Whether HSV affects MS risk remains controversial. In this study, HSV infection was modestly associated with MS risk according, especially in whites raising the possibility that the disparity between previous reports might be related to the racial make-up of study populations. We also confirm an interaction between HLA-DRB1 status and HSV infection and the risk of MS. Although DRB1 is more frequent in whites, a remote HSV infection was associated with increased MS risk only in HLA-DRB1*15:01 negative subjects, which is the reverse interaction we identified for prior EBV infection. Although the underlying reasons for these differences remain to be clarified, these results highlight the complexity of gene-environment interactions as infections with viruses from the same family may have opposing effects on MS risk in individuals with the same genotype.
We did not find any association between CMV and odds of pediatric MS. This is in line with a prior report in adults, but in contrast with two others in children. Two small groups of controls were used in our former study which could explain differences in the findings. One control group included subjects with inflammatory neurological diseases while the other was recruited during a different time period and from different sites compared with cases. In contrast, this study was a larger, multicenter study in which cases and controls were selected from the same populations and during the same time frame, and as such is more likely valid. In a recent case–control study in adult MS, CMV seropositivity was negatively associated with MS risk only in Hispanics, but not in Blacks or whites. This observation was interpreted as a support for the hygiene hypothesis, in which lack of exposure to common pathogens in childhood increases the risk of autoimmune disease later in life.

When using genetic ancestry data rather than self-reported race, the associations between viral serostatus and risk of pediatric MS remained unchanged except for HSV possibly because the genetic ancestry data were available for only a subset of participants, resulting in a 34% decreased sample size.

The strengths of our study include the large number of cases and controls with diverse racial and ethnic backgrounds recruited at several US centers, the relatively short disease duration of cases (mean < 1 year) and the adjusted analyses for several potential confounders. The study also has several limitations. Serological testing was done after disease onset and our sample is not population-based, that is, unknown selection bias may have influenced the results. Similar to all observational studies, unmeasured or unknown confounders might have affected the results. As mentioned previously, we did not analyze EBNA-1 seropositivity because the manufacturing source of the antigen changed during the study and the results were not consistent. While antibody responses against VCA are universally present in EBV exposed persons, EBNA-1 IgG is not produced in about 5% of patients after EBV infection and in some individuals, it may disappear over time. Hence, the anti-VCA IgG is a more reliable indicator of previous EBV exposure.

Although this study does not explain how environmental factors affect MS risk in children at the molecular level, it highlights the complexity of factors at play. Larger case–control studies will allow further modeling of the interactions between viral infections, and other environmental and genetic factors.

Acknowledgments

We thank the study coordinators at the participating sites, and the patients and controls, and their families for participating in this project.

Author Contributions

Bardia Nourbakhsh: study design, interpretation of data, manuscript composition. Alice Rutatangwa: manuscript composition. Michael Waltz: analysis and interpretation of data, manuscript composition. Mary Rensel: acquisition of data and manuscript composition. Manikum Moodley: acquisition of data and manuscript composition. Jennifer Graves: acquisition of data and manuscript composition. T. Charles Casper: analysis and interpretation of data, manuscript composition. Amy Waldman: acquisition of data and manuscript composition. Anita Belman: acquisition of data and manuscript composition. Benjamin Greenberg: acquisition of data and manuscript composition. Manu Goyal: acquisition of data and manuscript composition. Yolanda Harris: acquisition of data and manuscript composition. Ilana Kahn: acquisition of data and manuscript composition. Timothy Lotze: acquisition of data and manuscript composition. Soe Mar: acquisition of data and manuscript composition. Teri Schreiner: acquisition of data and manuscript composition. Gregory Aaen: acquisition of data and manuscript composition. Janace Hart: acquisition of data and manuscript composition. Jayne Ness: acquisition of data and manuscript composition. Jennifer Rubin: acquisition of data and manuscript composition. Jan-Mendelt Tillema: acquisition of data and manuscript composition. Lauren Krupp: acquisition of data and manuscript composition. Mark Gorman: acquisition of data and manuscript composition. Leslie Benson: acquisition of data and manuscript composition. Moses Rodriguez: acquisition of data and manuscript composition. Tanuja Chitnis: acquisition of data and manuscript composition. John Rose: acquisition of data and manuscript composition. Meghan Candee: acquisition of data and manuscript composition. Bianca Weinstock-Guttman: acquisition of data and manuscript composition. Xiaorong Shao: analysis and interpretation of data, manuscript composition. Lisa Barcellos: analysis and interpretation of data, manuscript composition. Judith James: analysis and interpretation of data, manuscript composition. Emmanuelle Waubant: study concept and design, funding for study, analysis and interpretation of data, manuscript composition, study supervision.

Conflict of Interest

The authors report no disclosure relevant to the manuscript.

References

1. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017;13:25–36.
2. Consorti -International Multiple Sclerosis Genetics, Patsopoulos N, Baranzini SE, Santanniello A, et al. The Multiple Sclerosis Genomic Map: role of peripheral immune cells and resident microglia in susceptibility. bioRxiv 2017;143933.

3. Sundqvist E, Bergström T, Daalhosein H, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2014;20:165–173.

4. Waubant E, Mowry EM, Krupp L, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011;76:1989–1995.

5. Hedström AK, Sundqvist E, Bäärnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain J Neurol 2011;134(Pt 3):653–664.

6. Sundqvist E, Sundström P, Lindén M, et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012;13:14–20.

7. Nielsen TR, Rostgaard K, Askling J, et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2009;15:431–436.

8. Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010;74:1905–1910.

9. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007;6:773–781.

10. Yea C, Tellier R, Chong P, et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 2013;81:1392–1399.

11. Lüneemann JD, Hoppe P, Roberts S, et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008;71:1033–1035.

12. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006;67:2063–2065.

13. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875–1879.

14. Langer-Gould A, Wu J, Lucas R, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. Neurology 2017;89:1330–1337.

15. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122–1126.

16. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019–3026.

17. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–219.

18. Chen C-Y, Pollack S, Hunter DJ, et al. Improved ancestry inference using weights from external reference panels. Bioinformatics 2015;29:1399–1406.

19. van der Mei I, Lucas R, Taylor B, et al. Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Mult Scler J 2016;22:461–469.

20. Handel AE, Williamson AJ, Disanto G, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 2010;5:e12496.

21. Levin Ll, Munger KL, O’Reilly EJ, et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010;67:824–830.

22. De Jager PL, Simon KC, Munger KL, et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70(13 Pt 2):1113–1118.

23. Krone B, Pohl D, Rostasy K, et al. Common infectious agents in multiple sclerosis: a case—control study in children. Mult Scler J 2008;14:136–139.

24. MacGregor HS, Latiwok QI. Complex role of gammaherpesviruses in multiple sclerosis and infectious mononucleosis. Neurol Res 1993;15:391–394.

25. Simmons A. Herpesvirus and multiple sclerosis. Herpes J IHMF 2001;8:60–63.

26. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083–3088.

27. Makhani N, Banwell B, Tellier R, et al. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler Houndmills Basingstoke Engl 2016;22:385–388.

28. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol 2012;1:31–43.

Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Number of subjects with available genetic ancestry data.

Table S2. Summary of the genetic ancestry data for the subset of participants with available data.